Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-10-2006 | ORIGINAL PAPER

(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population

Authors: Isabel Martínez-Gras, Janet Hoenicka, Guillermo Ponce, Roberto Rodríguez–Jiménez, Miguel Angel Jiménez-Arriero, Elena Pérez-Hernandez, Israel Ampuero, Jose Antonio Ramos-Atance, Tomas Palomo, Gabriel Rubio

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 7/2006

Abstract

The cannabinoid receptor 1 gene (CNR1) has been associated with addictive disorders and schizophrenia in different studies. We have compared the frequencies of the alleles for the 3′-UTR CNR1 microsatellite in a sample of 113 Spanish schizophrenic patients, including 68 with comorbid substance abuse, and 111 healthy controls. We report that the frequency of the allele 4 of this microsatellite is significantly lower in schizophrenia patients when compared with controls (χ² = 7.858; df 1; P = 0.005). No differences have been found with respect to substance abuse.

Thus, the allele 4 represents, in our sample, a protective factor against schizophrenia (odds ratio 0.468, 95% confidence interval (CI) 0.27–0.79). The population attributable genetic risk for the allele 4 absence is 30% (95% CI = 17–41%) and the attributable risk for the allele 4 absence in those with schizophrenia is 53% (95% CI = 20–73%). Our results suggest that, independent of substance abuse, differences in the cannabinoid system function could be involved in the vulnerability to schizophrenia in Spanish population.

Abramson JH, Gahlinger PM (2001) Computer programs for epidemiologists: Pepi version 4.0. Sagebrush Press, Salt Lake City

Andreasson S, Allebeck P, Engström A, Rydberg U (1987) Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet ii: 1483–1486CrossRef

Arndt S, Tyrrell G, Flaum M, Andreasen N (1992) Comorbidity of substance abuse and schizophrenia. The role of pre-morbid adjustment. Psychol Med 22:379–388PubMedCrossRef

Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Brit Med J 325:1212–1213PubMedCrossRef

Arseneault L, Cannon M, Witton J, Murray R (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117PubMedCrossRef

Blackwell J, Beresfors J (1987) Cannabis self-medication and adverse reactions in psychyatric patients. Soc Pharmacol 1:357–358

Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117–1127PubMedCrossRef

Caton C, Gralnick A, Bender S, Simon R (1989) Young chronic patients and substance abuse. Hosp Community Psychiatry 40:1037–1040PubMed

Chaudry HR, Moss HB, Bashir A, Suliman T (1991) Cannabis psychosis following bhang ingestion. Br J Addict 86:1075–1081PubMedCrossRef

Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990) Delta-9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156–162PubMedCrossRef

Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G (1997) Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 2:161–168PubMedCrossRef

Cuffel BJ (1992) Prevalence estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment Dis 180:589–592PubMedCrossRef

Dawson E (1995) Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiatr Genet 5 (S50–S51):850

Dean B, Sundram S, Bradbury R, Scarr E, Coplov D (2001) Studies on [3H] CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15PubMedCrossRef

Drake RE, Wallack MA (1989) Substance abuse among the chronic mentally ill. Hosp Community Psychiatry 40:1041–1045PubMed

Fergusson DM, Horwood LJ, Swain-Campbell NR (2003) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15–21PubMedCrossRef

Firsts MB, Spitzer RL, Gibbon M, et al. (1995) Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition (SCID-IP, Version 2.0). New York, NY: Biometric Research, New York State Psychiatric Institute

Gardner EL (1992) Cannabinoid interaction with brain reward systems. The neurobiological basis of cannabinoid abuse. In: Murphy L, Bartke A (eds) Marijuana/cannabinnoids. Neurobiology and neurophysiology. CRC Press, Boca Raton, FL, pp 275–335

Halikas JA, Goodwin DW, Guze SB (1972) Marihuana use and psychiatric illness. Arch Gen Psychiatry 27:162–165PubMed

Hoehe MR, Caenazzo L, Martínez MM, Hsieh WT, Modi WS, Gershon ES, Bonner TI (1991) Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14–q15. New Biol 3:880–885PubMed

Johnson JP, Muhleman D, Mc Murray J, Gade R, Verde R, Ask M, Kelley J, Comings DE (1997) Association between the cannaboind receptor gene (CNR1) and the P300 event-related potential. Mol Psychiatry 2:169–171PubMedCrossRef

Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178:116–122PubMedCrossRef

Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 15:401CrossRef

Lehman AF, Myers CP, Dixon LB, Johnson JL (1994) Defining subgroups of dual diagnosis patitns for service planning. Hosp Community Psychiatry 45(6):556–561PubMed

Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10(8):1665–1669PubMed

Li T, Liu X, Zhu ZH, Zhao J, Hu X, Ball DM, Sham PC, Collier DA (2000) No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 5:128–130PubMedCrossRef

Linzsen DJ, Dingemans PM, Leniorm ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51:273–279

Mathers DC, Ghodse AH (1992) Cannabis and psychotic illness. Br J Psychiatry 161:648–653PubMed

McGuire PK, Jones P, Harvey L (1994) Cannabis and acute psychosis. Schizophr Res 13:161–167PubMedCrossRef

Mueser KT, Drake RE, Wallach MA (1998) Dual diagnosis: a review of etiological theories. Addict Behav 23(6):717–734PubMedCrossRef

Negrete JC (1989) Cannabis and schizophrenia. Br J Addict 84:349–351PubMedCrossRef

Osher F, Kofoed L (1989) Treatment of patients with psychiatric and psychoactive substance abuse disorders. Hosp Community Psychiatry 40:1025–1030PubMed

Ponce G, Hoenicka J, Rubio G, Ampuero I, Jiménez-Arriero MA, Rodríguez-Jiménez R, Palomo T, Ramos JA (2003) Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol Psychiatry 8:466–467PubMedCrossRef

Racz I, Bilkei-Gorzo A, Toth ZE, Michel K, Palkovits M, Zimmer A (2003) A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 23:2453PubMed

Rubio G (1999) Consumo de cannabis en diferentes grupos de población. In: Cabrera J (ed) Cannabis Hasta dondel Jornadas de expertos en cannabis en la Comunidad de Madrid, Comunidad de Madrid Agenica Antidrogal, pp 167–184

Rubio G, Casas M (2001) Revisión del tratamiento de la esquizofrenia en individuos con abuso de drogas. Act Esp Psiquiat 29:124–130

Schneier FR, Siris SG (1987) A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis 175:641–652PubMedCrossRef

Shearn C, Fitzgibbons D (1972) Patterns of dugs use in a population of youthful psychiatric patients. Am J Psychiatry 128:65–71

Schmidt LG, Samochowiec J, Finckh U, Fiszer-Piosik E, Horodnicki J, Wendel B, Rommelspacher H, Hoehe MR (2002) Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 65:221–224PubMedCrossRef

Test MA, Wallisch DJ, Allness D, Ripp K (1989) Substance use in young adults with schizophrenic disorders. Schizophrenia Bull 15:465–476

Tsai SJ, Wang YC, Hong CJ (2000) Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatric Genet 10:149–151CrossRef

Turner VM, Tsuang MT (1990) Impact of substance abuse on the course and outcome of schizophrenia. Schizophrenia Bull 16:87–95

Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, Fujiwara Y, Sakai A, Kuroda S (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7:515–518PubMedCrossRef

Van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156:19–27

Weiser M, Knobler HY, Noy S, Kaplan Z (2002) Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 114:949–955PubMedCrossRef

Zammit S, Allebeck P, Andreasson S, Lundberg l, Lewis G (2002) Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Brit Med J 325:1199–1201PubMedCrossRef

Zhang PW, Isighuro H, Ohtsuki T, Hess J, Carillo F, Walther D, Onaivi ES, Arinami T, Uhl GR (2004) Human cannabinoid receptor 1:5’ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysusbstance abuse. Mol Psychiatry 9:916–931PubMedCrossRef

Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulated cortex in schizophrenia. Pro. Neuropsychopharmacol Biol Psychiatry 28:355–360PubMedCrossRef

Ujike H, Morita Y (2004) New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 96(4):376–381PubMedCrossRef

Title: (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population
Authors: Isabel Martínez-Gras
Janet Hoenicka
Guillermo Ponce
Roberto Rodríguez–Jiménez
Miguel Angel Jiménez-Arriero
Elena Pérez-Hernandez
Israel Ampuero
Jose Antonio Ramos-Atance
Tomas Palomo
Gabriel Rubio
Publication date: 01-10-2006
Publisher: Steinkopff-Verlag
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 7/2006
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-006-0665-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2006

Gender- and violence-related prevalence of mental disorders in prisoners

Obstetric complications and neurological abnormalities in neuroleptic-naive psychotic patients

Comorbidity of anxiety disorders in patients with remitted bipolar disorder

Is the association of alcohol use disorders with major depressive disorder a consequence of undiagnosed bipolar-II disorder?

Neurocognitive functioning in patients with first-episode schizophrenia

Serum BDNF, TNF-α and IL-1β levels in dementia patients